Gene Silencing/Gene Editing | Gene News GenomeWeb

Gene Silencing/Gene Editing

The Atlanta-based firm seeks to develop antiviral genome-targeting therapies for HBV and HPV using CRISPR/Cas9.

The gene editing firm has sold all 5.9 million shares offered to the public as well as 885,000 shares in the fully exercised over-allotment option to the underwriters.

For several reasons, scientists, as well as gene editing therapy company Editas, think that the first clinical trials for CRISPR-based cures will be for hereditary eye diseases.

The Cambridge, Massachusetts-based gene editing firm will offer 5.9 million shares of common stock, for a total of $94.4 million.

The research project, led by Kathy Niakan of the Francis Crick Institute, will involve editing several genes thought to be important to embryo development.

Hybrid promoter and recombinant vector comprising the same
Switchable gRNAs comprising apatamers
Methods and compositions for selecting siRNA of improved functionality
miRNA fingerprint in the diagnosis of diseases
Methods for identifying a target site of a Cas9 nuclease
Compositions and methods for inhibiting expression of the ALAS1 gene

Editas Files for IPO

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.